{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:18:04Z","timestamp":1780535884265,"version":"3.54.1"},"reference-count":56,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T00:00:00Z","timestamp":1253577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:p>The review focuses on the central neuronal circuits involved in energy homeostasis and the opportunities these offer for pharmacological intervention to decrease feeding behaviour and reduce weight. This article is based on the presentation \u2018<jats:italic>New central targets for the treatment of obesity<\/jats:italic>\u2019 (Sargent, British Pharmacological society, Clinical Section Symposium, December 2008).<\/jats:p><jats:p>Central neuronal substrates controlling weight offer numerous opportunities for pharmacological intervention. These opportunities range from non\u2010specific enhancement of monoamine signalling (triple reuptake inhibitors) to targeting specific monoamine receptor subtypes (5\u2010HT<jats:sub>2c<\/jats:sub> and 5\u2010HT<jats:sub>6<\/jats:sub>). The data reviewed suggest that these approaches will lead to weight loss; whether this is sufficient to produce clinically meaningful effect remains to be determined. Combination therapy targeting more than one mechanism may be a means of increasing the magnitude of the response. Preclinical studies also suggest that novel approaches targeting specific neuronal pathways within the hypothalamus, e.g. MCH<jats:sub>1<\/jats:sub> receptor antagonism, offer an opportunity for weight reduction. However, these approaches are at an early stage and clinical studies will be needed to determine if these novel approaches lead to clinically meaningful weight loss and improvements in co\u2010morbid conditions such as diabetes and cardiovascular disorders.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2009.03550.x","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T14:24:48Z","timestamp":1253629488000},"page":"852-860","source":"Crossref","is-referenced-by-count":60,"title":["New central targets for the treatment of obesity"],"prefix":"10.1111","volume":"68","author":[{"given":"Bruce J.","family":"Sargent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,27]]},"reference":[{"key":"e_1_2_13_2_2","unstructured":"Center for Disease Control and Prevention. Available athttp:\/\/www.cdc.gov\/nccdphp\/dnpa\/obesity\/trend\/maps\/(last accessed 14 October 2009)."},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddstr.2008.05.005"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddstr.2008.07.001"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910073411501"},{"key":"e_1_2_13_6_2","first-page":"219","article-title":"National medical spending attributable to overweight and obesity: how much, and who's paying?","volume":"3","author":"Finkelstein EA","year":"2003","journal-title":"Health Affairs"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1353\/foc.2006.0004"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1124\/mi.8.2.6"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2007.10.009"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/35007534"},{"key":"e_1_2_13_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1630"},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2007.10.006"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2008.01492.x"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2007.09.003"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2007.06.004"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2331"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2008.08.007"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2008.01.008"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2006.04.020"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.04.001"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2008.06.028"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.59.2.2"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(00)00105-4"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152706777452254"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301155"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00216-8"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39385.413113.25"},{"key":"e_1_2_13_28_2","unstructured":"GreenappleR. Available athttp:\/\/www.fiercepharma.com\/special\u2010reports\/can\u2010obesity\u2010treatment\u2010be\u2010cost\u2010effective(last accessed 15 October 2009)."},{"key":"e_1_2_13_29_2","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0140-6736(08)61525-1","article-title":"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double\u2010blind, placebo\u2010controlled trial","volume":"372","author":"Astrup A","year":"2008","journal-title":"Lancet"},{"key":"e_1_2_13_30_2","unstructured":"Company information. Available athttp:\/\/www.medicalnewstoday.com\/articles\/83621.php(last accessed 15 October 2009)."},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.09.033"},{"key":"e_1_2_13_32_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.038083"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2006.06.004"},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.10.008"},{"key":"e_1_2_13_35_2","unstructured":"Company information. Available athttp:\/\/www.arenapharm.com(last accessed 15 October 2009)."},{"key":"e_1_2_13_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.08.006"},{"key":"e_1_2_13_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00056-9"},{"key":"e_1_2_13_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706807"},{"key":"e_1_2_13_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2008.00520.x"},{"key":"e_1_2_13_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2008.09.001"},{"key":"e_1_2_13_41_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00545.2002"},{"key":"e_1_2_13_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.7.761"},{"key":"e_1_2_13_43_2","unstructured":"PliethJ.Obesity: what next after the CB1 antagonists' failure?Scrip2008; 7 November 2008 44\u20137."},{"key":"e_1_2_13_44_2","unstructured":"Company information. Available athttp:\/\/www.orexigen.com(last accessed 15 October 2009)."},{"key":"e_1_2_13_45_2","unstructured":"Company information. Available athttp:\/\/www.vivus.com(last accessed 15 October 2009)."},{"key":"e_1_2_13_46_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.029991"},{"key":"e_1_2_13_47_2","first-page":"1198","article-title":"Neuropeptide Y Y5 receptor antagonists as anti\u2010obesity drugs","volume":"4","author":"Levens NR","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_13_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.08.002"},{"key":"e_1_2_13_49_2","unstructured":"Company information. Available athttp:\/\/www.shionogiusa.com\/media.html(last accessed 15 October 2009)."},{"key":"e_1_2_13_50_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.phrs.2008.10.005","article-title":"Brain effects of melanocortins","volume":"59","author":"Bertolini A","year":"2008","journal-title":"Pharmacological Res"},{"key":"e_1_2_13_51_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31743"},{"key":"e_1_2_13_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2007.05.029"},{"key":"e_1_2_13_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.08.010"},{"key":"e_1_2_13_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.06.027"},{"key":"e_1_2_13_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)02146-0"},{"key":"e_1_2_13_56_2","unstructured":"SargentB SurmanM FreemanE GrabowskiJ JiangX\u2010W JiangG HaddenM LucheM KhmelnitskyY LindsayJ MozhaevaL ZarembaJ ViggersJ VickersS GoddardS CheethamS GuzzoP.Comparative pharmacology of AMR\u2010MCH\u20101 and AMR\u2010MCH\u20102 MCH1 receptor antagonists for the treatment of obesity. Proceedings of the British Pharmacological Society (2008) Available athttp:\/\/www.pA2online.org\/abstracts\/Vol6Issue4abst114P.pdf(last accessed 15 October 2009)."},{"key":"e_1_2_13_57_2","unstructured":"Company information. Available athttp:\/\/www.neurogen.com\/index.php?option=com_content&view=article&id=63&Itemid=78&p=irol\u2010news(last accessed 15 October 2009)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03550.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03550.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:08:26Z","timestamp":1697418506000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03550.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,27]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03550.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03550.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,27]]}}}